摘要
目的系统评价复方阿嗪米特治疗胆囊切除术后功能性消化不良(FD)的疗效及安全性,为临床提供依据。方法检索国内外数据库有关复方阿嗪米特治疗胆囊切除术后功能性消化不良的随机对照试验,应用Revman5.3软件进行Meta分析。结果共13篇随机对照试验,包括1 250例患者符合入选标准。Meta分析结果显示:复方阿嗪米特组治疗功能性消化不良的总有效率显著高于常规治疗组(89.7%vs.61.1%,RR=1.42,95%CI:1.18~1.70,P<0.05),尤其对于有食欲不振(RR=2.15,95%CI:1.57~2.95,P<0.05)以及腹痛或腹部不适(RR=2.19,95%CI:1.35~3.56,P<0.05)的患者。各项研究均未报道严重不良反应。结论复方阿嗪米特是一种治疗胆囊切除术后功能性消化不良的有效药物,且安全性高。
Objective To systematically evaluate the efficacy and safety of compound azintamide in treatment of patients with functional dyspepsia（FD） after cholecystectomy,and provide basis for the clinical treatment. Methods The databases were searched at home and abroad to collect randomized controlled trials for comparing the efficacy and safety of compound azintamide with other regular treatment. Meta-analysis was performed with Revman 5.3 software. Results A total of 13 randomized controlled trials including 1250 patients met the inclusion criteria. The Meta-analysis showed that the total effective rate in the treatment group was significantly higher than that in control group（89.7%vs. 61.1%,RR=1.42,95%CI：1.18~1.70,P〈0.05）,especially for the patients with loss of appetite（RR=2.15,95%CI：1.57~2.95,P〈0.05）and abdominal pain or discomfort（RR=2.19,95%CI：1.35~3.56,P〈0.05）. No serious adverse events were reported in the included studies. Conclusion The compound azintamide is effective and safe in the treatment of FD after cholecystectomy.
出处
《热带医学杂志》
CAS
2017年第11期1494-1498,1506,共6页
Journal of Tropical Medicine
